Semaglutide
Also known as: Ozempic (brand), Wegovy (brand)
Semaglutide is a GLP-1 receptor agonist approved in Australia as a prescription medicine for type 2 diabetes and, under separate branding, weight management. Compounded and grey-market versions are not approved.
- Category
- Metabolic / GLP-1
- Reported half-life
- Reported ~7 days, allowing once-weekly dosing of the approved injectable product
- Common forms
- Pre-filled injection pen (approved prescription product), Tablet (approved oral formulation in some markets), Compounded/grey-market vials (not approved)
- Research status
- Prescription-only medicine in Australia (approved by the TGA for specified indications). Compounded and grey-market versions are not approved and fall outside the regulated supply chain.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Demonstrated in clinical trials to lower blood glucose in type 2 diabetes
- Shown in trials to support weight reduction alongside diet and lifestyle
- Reported to reduce appetite and slow gastric emptying
- Some trials report cardiovascular risk-reduction benefits in certain populations
How it is reported to work
Semaglutide is reported to mimic GLP-1, a gut hormone that stimulates insulin release when blood sugar is high, suppresses glucagon, and slows the rate at which the stomach empties. These actions are reported to reduce appetite and improve blood-glucose control. Unlike many peptides on this site, these mechanisms are supported by large, peer-reviewed human clinical trials.
Background
Semaglutide is a GLP-1 receptor agonist, a class of medicine that mimics a naturally occurring gut hormone. It is sold under brand names such as Ozempic (for type 2 diabetes) and Wegovy (for weight management). Unlike many of the research peptides documented on this site, semaglutide is an approved prescription medicine in Australia with a substantial clinical-trial evidence base. This page is educational and is not medical advice; it does not recommend use.
What the research actually shows
Semaglutide has been studied in large, randomised human trials. The SUSTAIN programme examined its effects on blood glucose in type 2 diabetes, and the STEP programme examined weight outcomes. These trials demonstrated meaningful effects on glucose control and body weight. Even so, results vary between individuals, and the medicine carries side effects that require professional oversight.
| Programme | Focus | Outcome reported |
|---|---|---|
| SUSTAIN | Type 2 diabetes | Improved glucose control |
| STEP | Weight management | Reduced body weight |
What it is used for (regulated indications)
In Australia, semaglutide is prescribed for type 2 diabetes and, under separate branding and indication, chronic weight management in eligible patients. These uses are determined by a healthcare professional based on individual assessment, not by self-selection.
Things to be aware of
A key distinction: the approved, TGA-regulated product is very different from compounded or grey-market “semaglutide” sold outside the regulated supply chain. The latter is not approved, and its purity and contents cannot be assured, which is why independent testing is discussed in this community. Reported side effects include nausea and other gastrointestinal effects, and rarer serious reactions are possible.
Because semaglutide is prescription-only, it should only be used under medical supervision. This article explains what semaglutide is and what the evidence shows; it is not an endorsement and does not tell anyone to obtain or use it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Strong, trial-backed blood-glucose control in type 2 diabetes
- Significant reported weight reduction alongside diet and lifestyle
- Reported appetite suppression and reduced food cravings
- Once-weekly dosing of the approved product is convenient for many
- Cardiovascular risk reduction reported in some high-risk populations
Common side effects
- Nausea, especially when starting or increasing dose
- Vomiting, diarrhoea or constipation
- Reduced appetite, early fullness and burping
- Fatigue and mild headaches
- Injection-site reactions
Rare / serious side effects
- Pancreatitis (severe, persistent abdominal pain) - seek urgent care
- Gallbladder problems, including gallstones
- Severe dehydration that can affect kidney function
- Allergic reactions
- Reports of changes in vision in some diabetic patients
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Semaglutide. Listed so you can make an informed decision, not to suggest any use is safe.
- Rapid dose escalation (skipping the gradual titration) is reported to cause severe, prolonged nausea and vomiting
- Severe vomiting/diarrhoea from overuse can cause dehydration, which is reported to lead to acute kidney injury, a known concern with GLP-1 overuse
- Using unregulated compounded or grey-market vials has led to reported dosing errors and overdoses, partly due to inconsistent concentrations
- Very rapid weight loss from excessive dosing is reported to be associated with muscle-mass loss and gallstones
- Combining with other appetite suppressants is reported to amplify gastrointestinal and dehydration risks
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Appetite changes are often reported within the first week; meaningful weight and glucose changes build over several months.
First effects
Appetite drop within days
Noticeable change
Weight/glucose ~4 weeks
Clear results
Steady loss by ~12 weeks
Peak effect
Plateau ~6–9 months
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Semaglutide. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection (approved pen); compounded vials drawn with an insulin syringe |
|---|---|
| Typical reported dose | Reported: start 0.25 mg/week for 4 weeks, then 0.5 mg, titrating up toward 1.0–2.4 mg/week |
| Frequency | Once weekly |
| Cycle length | Ongoing maintenance medication (not a short cycle); effects reverse after stopping |
Reported reconstitution (mg → units)
Example for a compounded vial: a 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2.5 mg/mL. A 0.25 mg dose ≈ 0.1 mL = 10 units on a U-100 insulin syringe; a 0.5 mg dose ≈ 0.2 mL = 20 units. (The approved pen is pre-dosed, no maths needed.)
Work out the units for your vial → CalculatorThe approved prescription product is reported to be titrated slowly, typically starting at a low weekly dose and increasing in steps over several weeks to a maintenance dose, specifically to limit nausea. It is used as an ongoing weekly treatment under medical supervision, not a short cycle. Stopping is commonly reported to lead to appetite and weight rebound. These are reported patterns for the regulated medicine only and are not a recommendation; dosing must be set by a prescriber.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
An alternative incretin medicine; people compare or switch, not combine
Studied together as CagriSema in trials
Resistance training & protein intake
Commonly paired to limit reported muscle-mass loss during weight loss
Safety notes
As a prescription-only medicine, semaglutide should only be used under the supervision of a qualified healthcare professional who can assess suitability and monitor for side effects such as nausea, gastrointestinal upset and rarer serious reactions. Compounded or grey-market versions are not TGA-approved and their quality and contents cannot be assured. Do not use any version without appropriate medical guidance.